HBM Holdings Limited
和鉑醫藥控股有限公司
10 DEC 2020
HBM Holdings Limited is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapies that address critical unmet medical needs for patients around the world. Focusing on the immunology and oncology disease areas, the Company has built a portfolio of more than ten potentially differentiated drug candidates.
The Company’s antibody discovery engine empowers the development of next generation therapeutic antibodies. Harbour Mice® generates fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) focuses on generating differentiated HCAb-based bispecific immune cell engagers potentially capable of delivering tumor-killing effects unachievable by combination therapies.
和鉑醫藥控股有限公司是一家臨床階段生物製藥公司，從事發現及開發免疫及腫瘤疾病方面的差異化抗體療法，以應付未獲滿足的醫療需求。公司專注於免疫與腫瘤疾病領域，已拓展了多於十種可能成為差異化候選藥物的產品管線。
和鉑醫藥的抗體開發平台是研發新一代治療性抗體的引擎。Harbour Mice® 平台擁有能夠產生兩條重鏈和兩條輕鏈的全人源抗體的H2L2平台技術以及能夠產生全人源重鏈抗體的HCAb平台技術。公司還基於HCAb開發了免疫細胞銜接器平台（HBICE™）專注於生成差異化的基於HCAb的免疫細胞銜接器的雙特異性抗體，有望實現聯合療法所未能達到的腫瘤消除療效。